Several next‐generation sequencing techniques have been developed to detect BRCA1 and BRCA2 mutations33, 34 and thanks to the clinical application of PARP, an effective and reliable detection of these mutations in formalin‐fixed and paraffin embedded (FFPE) tissue samples has recently been developed.35 With the development of mutation detecting techniques, the clinical affirmation of our research will be possible although a large cohort will be needed because of the low mutation rate of BRCA in the whole heterogenic colony of ovarian cancer. The gene discussed is BRCA2; the disease is ovarian cancer.